Use of Tamoxifen in Systemic Mastocytosis

Status Completed

Clinical Trial Summary

In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Clinical Trial Description

Not desired ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01334996
Study type	Observational
Source	Mayo Clinic
Contact
Status	Completed
Phase
Start date	February 2005
Completion date	August 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01807598` - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	Phase 2
Completed	`NCT00171912` - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2
Completed	`NCT02441166` - Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis	N/A
Withdrawn	`NCT03739606` - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Phase 2
Not yet recruiting	`NCT00979160` - Evaluation of Response of Dasatinib to Treat Mastocytosis	Phase 2
Active, not recruiting	`NCT04681105` - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Phase 1
Recruiting	`NCT01602939` - Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis	Phase 2/Phase 3
Completed	`NCT03401060` - Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	Phase 3
Terminated	`NCT02415608` - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	Phase 2
Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
Terminated	`NCT00918931` - Obatoclax for Systemic Mastocytosis	Phase 2
Completed	`NCT00493129` - Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)	Phase 2
Completed	`NCT01297777` - Imatinib in KIT-negative Systemic Mastocytosis	Phase 4
Terminated	`NCT03214666` - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT00449748` - Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis	Phase 2
Completed	`NCT00109707` - A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies	Phase 1/Phase 2